Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can
exist as it’s alone or conjugated with other psychiatric problems. Insomnia is most common
is women and the severity may increase in conditions like pregnancy, postpartum, and
menopause. The exact cause of insomnia is still a mystery. Many research has shown that
biological, behavioural and psychological factors are responsible for initiating of insomnia.
Different types of treatment are available in the market- Pharmacological and non-
pharmacological treatment. Global Insomnia market is driving due to increase in the
number of insomnia patient across the globe, technological advances and many other. While
lack of education and awareness is the major restraining factor for the growth of market.
Global Insomnia Market is expected to grow at a CAGR of 4.5% during forecasted period of
2017-2023.
Segmentation: Global Insomnia Market has been segmented on the basis of types of
therapy which comprises Pharmacological therapy which is further sub segmented into
benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non
Pharmacological therapy which is sub segmented into Relaxation therapy, Cognitive
Behavioral Therapy, Sleep Hygiene Education, Stimulus Control, Paradoxical Intention and
Other. By drug formulation they are segmented as Capsules, Tablet and others. On the
basis of condition of diseases they are poor quality of sleep, sleep maintenance and other.
Get Sample Copy at http://bit.ly/2pL6upm .
Key Players for Global Insomnia market: Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co
Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer
Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer
Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn
Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim
(Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).
On regional basis the Global Insomnia Market is segmented into four regions- North
America, Europe, Asia Pacific and Middle East and Africa. Due to introduction of new
technology and new treatments North America is has the highest market for insomnia
followed by Europe. Increasing stress is the major problem for increasing the insomnia
market in North America and Europe. Asia Pacific and Middle East and Africa has the lowest
market for insomnia.
Ask Query to Expert at http://bit.ly/2pHp9TV .
Top Reasons to Buy the Reports:
Company profiling with detailed strategies, financials, and recent development
activities
Market Strategic Business Influence Data